OAB-047: Plasma cell disorder patients are left vulnerable after one dose of the BNT162b2 mRNA or the ChAdOx-nCOV-19 COVID-19 vaccines

Background null Concerns have been raised about the ability of patients with plasma cell disorders (PCD) to mount adequate immune responses to vaccination, particularly considering the initial extension to vaccination intervals in the United Kingdom to up to 12 weeks in December 2020, the start of the vaccination roll-out. Protecting this vulnerable patient group with anti-SARS-CoV-2 vaccination is critical. null Methods null We measured the...